TP53 and neoplasm: However, the antitumor efficacy of wild-type p53-targeting DC vaccine therapy is limited due to weak p53 immunogenicity in tumor cells, poor tumor-infiltration of CTLs, and formation of an immunosuppressive tumor microenvironment (TME).